Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia

Journal of Infection and Chemotherapy

Volumn 19, Issue 1, 2013, Pages 103-111

  Nakagawa, Yasunori ^a   Suzuki, Keishi ^a   Ohta, Kensuke ^b   Hino, Masayuki ^c   Ohyashiki, Kazuma ^d   Kanamaru, Akihisa ^e   Tamura, Kazuo ^f   Urabe, Akio ^g   Masaoka, Tohru ^h  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b SAISEIKAI NAKATSU HOSPITAL   (Japan)

^c Osaka Prefecture University   (Japan)

^d TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^g Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^h OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Antibiotic; Combination; Febrile neutropenia; Infection; Monotherapy

Indexed keywords

AMIKACIN; CEFEPIME; CIPROFLOXACIN; MEROPENEM; PANIPENEM PLUS BETAMIPRON;

ADOLESCENT; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FUNGUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPHIL COUNT; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 84874038970     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0466-8     Document Type: Article

References (20)

1. De Pauw BE, Donnelly JP, Raemakers JMM. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother. 1995;36:185-200.
2. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared to piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med. 1994;120:834-44.
3. Ramphal R. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenia patient. Am J Med 1996;100(6A):83S-8S
4. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother. 1996;40:1108-15.
5. Breen J, Ramphal R, Cometta A, Conetta B, Nicaise J. Cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. In: Klastersky J, editor. Febrile neutropenia. Berlin: Springer; 1997. p. 63-74.
6. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551-73.
7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51 (Epub 2002 Feb 13).
8. Masaoka T. Evidence-based recommendations on antimicrobial use in febrile neutropenia in Japan. Clin Infect Dis. 2004;39(suppl 1):S49-52.
9. Tamura K, Imajo K, Akiyama N, Suzuki K, Urabe A, Ohyashiki K, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Japan Febrile Neutropenia Study Group. Clin Infect Dis 2004;39(suppl 1):S15-S24.
10. Rolston K VI, Raad I, Whimbey E, Bodey GP. The changing spectrum of bacterial infections in febrile neutropenic patients. In: Klastersky J, editor. Febrile neutropenia. Berlin: Springer; 1997. p. 53-56.
11. Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination on 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol. 2002;71:248-55.
12. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents. 2003;21:392-402.
13. Shibata H, Yamane T, Sakamoto E, Nakamae H, Ohta K, Hino M. Clinical analysis of antibiotic treatment for febrile neutropenia. Jpn J Antibiot. 2005;58:382-7. (in Japanese).
14. Salazar R, Solá C, Maroto P, Tabernero JM, Brunet J, Verger G, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:27-33.
15. Sugiyama H, Horiuchi A, Hasegawa H, Kitani T, Tagawa S, Masaoka T, et al. Therapeutic effects of meropenem against severe infections in patients with hematopoietic disorders: Hanshin Study Group of Hematopoietic Disorders and Infection. Jpn J Antibiot. 1992;45:687-96. (in Japanese).
16. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994;30A:430-7.
17. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 1995;39:445-52.
18. González-Barca E, Fernández-Sevilla A, Carratalá J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microb Infect Dis. 1996;15:291-6.
19. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
20. Corey L, Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med. 2002;346:222-4.